Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pharmaceutical Single-Use Filling Assemblies – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pharmaceutical Single-Use Filling Assemblies market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and biotech companies, the aseptic filling of sterile liquid products (biologics, vaccines, gene therapies, monoclonal antibodies) into vials, syringes, or cartridges presents significant operational challenges. Traditional stainless steel filling lines require extensive cleaning and sterilization between batches (CIP/SIP: clean-in-place/steam-in-place), leading to 24-72 hours of downtime per product changeover, risk of cross-contamination (residual product or cleaning agents), and high capital investment for multi-product facilities. Pharmaceutical single-use filling assemblies address these pain points as pre-sterilized, disposable systems designed for aseptic filling. These assemblies typically include tubing, connectors, manifolds, filters, and sterile fluid-contact components, all integrated into a single-use format to eliminate the need for cleaning and sterilization between batches. By employing single-use technology, manufacturers can minimize downtime (changeover reduced from 2-3 days to 2-4 hours), streamline changeovers between different products, and comply with stringent regulatory standards for aseptic processing. The global market was valued at US3,067millionin2025andisprojectedtoreachUS3,067millionin2025andisprojectedtoreachUS 7,145 million by 2032, growing at a CAGR of 13.0%—driven by biologics expansion, vaccine manufacturing, and CMO adoption. The gross profit margin for this product category is approximately 20%.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5514230/pharmaceutical-single-use-filling-assemblies
1. Market Size & Share Outlook: Explosive Growth Driven by Biologics and CMO Expansion
The global market for pharmaceutical single-use filling assemblies is experiencing explosive growth, driven by increasing demand for biologics, vaccines, and advanced therapies (cell and gene therapies), which require flexible, efficient, and contamination-free manufacturing processes. Regulatory authorities are enforcing stricter Good Manufacturing Practice (GMP) standards for sterile injectable products, further encouraging adoption of disposable systems. The market was valued at US3,067millionin2025andisprojectedtoreachUS3,067millionin2025andisprojectedtoreachUS 7,145 million by 2032, representing a CAGR of 13.0%—significantly outpacing the broader pharmaceutical equipment market (5-6% CAGR).
Recent market intelligence (Q1 2026): Preliminary supply-side data indicates that market share concentration among the top five manufacturers—Sartorius, Thermo Fisher Scientific, Merck, Avantor, and Cytiva—remains significant at approximately 50-55% of the global market. Sartorius leads in single-use filling assemblies (Flexsafe, Biostat) with integrated sterile connectors and customized manifolds. LePure Biotech (China) and Cobetter Filtration (China) are gaining market share in Asia-Pacific (20-25% local share, up from 10-15% in 2020), driven by domestic biopharma expansion and price advantages (20-30% below Western brands). ZACROS (Japan) and Repligen (US) hold niche positions in specialized assemblies for cell and gene therapies.
Market drivers: Single-use assemblies simplify upstream and downstream operations (cell culture, filtration, aseptic transfer, and fill-finish) by eliminating cleaning and sterilization steps between batches, reducing cross-contamination risks, and enhancing overall operational efficiency. The growing trend of outsourcing production to CMOs increases demand for modular, standardized, and rapidly deployable assemblies that can handle multiple clients and product types. Innovations in pre-sterilized kits, customizable manifolds, and integrated monitoring sensors support market expansion by improving process reliability and reducing validation time.
2. Technology Deep Dive: Universal vs. Customized Assemblies
Pharmaceutical single-use filling assemblies are pre-sterilized, disposable systems designed for the aseptic filling of liquid pharmaceutical products into vials, bottles, syringes, or other containers. They are compatible with various filling machines and can be customized to suit specific drug formulations, volumes, and container types. These assemblies are primarily used to maintain product sterility, reduce cross-contamination risk, and improve operational efficiency in pharmaceutical manufacturing.
Market segmentation by assembly type:
- Universal (Standard) Assemblies (~35-40% of market share by volume, lower by value) – Pre-configured, off-the-shelf assemblies designed for common applications (small molecule sterile injectables, standard vial filling, 1-50 mL fill volumes). Advantages: lower cost (US$ 50-200 per assembly), immediate availability (no lead time for design/engineering), validated for common drug formulations (reduced user validation burden). Disadvantages: limited customization, may not be optimized for sensitive biologics (protein adsorption concerns, extractables/leachables testing required). Universal assemblies dominate in CMO facilities running multiple client products with standard configurations and in less-sensitive sterile manufacturing. Leading universal assembly brands: Thermo Fisher (SteriFill), Sartorius (Flexsafe Standard), Avantor (MasterFlex).
- Customized Assemblies (dominant and fastest-growing segment, ~60-65% of market share by value, growing at 15-18% CAGR) – Engineered-to-order assemblies for specific drug products: specialized tubing lengths (1-10 meters), multiple manifolds (2-8 inlet ports), integrated sterile connectors (aseptic couplings), custom filters (0.2 μm or 0.1 μm, pre- and post-sterilizing), and specific bag materials (low-protein-binding, low-extractable films). Customized assemblies are required for biologics (monoclonal antibodies, fusion proteins, cytokines), vaccines (mRNA, viral vectors), and cell/gene therapies (sensitive to materials, need validated extractables profiles). Advantages: optimized for specific product (minimized hold-up volume, reduced protein adsorption, validated extractables/leachables), improved process consistency, reduced risk of contamination (fewer manual connections). Disadvantages: higher cost (US$ 200-1,500 per assembly), longer lead time (4-12 weeks for design, engineering, and gamma irradiation), requires dedicated validation per product. Leading customized assembly brands: Sartorius (Flexsafe Custom), Merck (Millipore Custom Assemblies), Cytiva (ReadyToProcess Custom), LePure Biotech (custom engineering).
Industry insight (manufacturing scale segmentation): The pharmaceutical single-use filling assembly market exhibits clear product tiering: Pre-clinical and Phase I/II clinical trial supply (small batches, 100-1,000 units per batch) favors universal assemblies (lower cost, faster availability). Phase III and commercial manufacturing (large batches, 10,000-500,000 units per batch) requires customized assemblies (optimized for high-speed filling machines, validated extractables profile for regulatory submission). CMOs serving multiple clients stock 30-50 universal assembly configurations (covering 80-90% of client needs) but will engineer custom assemblies for high-volume or sensitive biologic programs (10-20% of volume but 40-50% of revenue).
3. Market Drivers: Biologics Pipeline, Vaccine Manufacturing, and CMO Adoption
Three factors are driving the pharmaceutical single-use filling assembly market:
First, biologics and advanced therapy pipeline expansion. As of Q1 2026, FDA has approved 15+ monoclonal antibodies (mAbs), 10+ gene therapies (including Luxturna, Zolgensma, Hemgenix, Elevidys, Roctavian, etc.), and 12+ cell therapies (CAR-T: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti). Late-stage pipeline includes 50-70 additional biologics and 100+ advanced therapies. Each biologic product requires dedicated fill-finish assemblies (customized for specific fill volume, container type, and drug formulation). Average commercial biologic requires 50,000-500,000 filling assemblies annually (1 assembly per 50-200 units filled, depending on vial size and assembly hold-up volume). This translates to US$ 50-500 million annual assembly revenue per large biologics manufacturer (Sanofi, Roche, J&J, Pfizer, Novartis, Merck, AbbVie, Amgen).
Second, vaccine manufacturing and pandemic preparedness. COVID-19 vaccine manufacturing (2021-2023: 13 billion doses) accelerated single-use filling assembly adoption: mRNA vaccines (Pfizer/BioNTech, Moderna) required 1,000-5,000 assemblies per manufacturing site weekly; viral vector vaccines (J&J, AstraZeneca) required similar volumes. Governments (US BARDA, EU HERA, WHO) are stockpiling single-use assemblies for pandemic response (target 30-90 day supply for rapid scale-up). Seasonal influenza, HPV, pneumococcal, and emerging pathogen vaccines (RSV, avian influenza, Nipah) also require single-use assemblies, with global vaccine filling assembly market estimated at US$ 500-800 million annually and growing 8-10% CAGR.
Third, outsourcing to CMOs and CDMOs. The pharmaceutical outsourcing market (CMO/CDMO) is projected to reach US150−200billionby2028,withfill−finishservicesrepresenting15−20150−200billionby2028,withfill−finishservicesrepresenting15−20 25-40 billion). CMOs prefer single-use filling assemblies because: (1) rapid changeover between clients (2-4 hours vs. 2-3 days for stainless steel), (2) reduced cross-contamination risk (no shared fluid contact surfaces), (3) lower capital investment (no CIP/SIP systems required), (4) flexibility to handle 10-50 different client products per year. CMOs (Lonza, Catalent, Samsung Biologics, WuXi Biologics, Recipharm, Thermo Fisher’s Patheon) are the fastest-growing customer segment for single-use filling assemblies (18-20% CAGR), representing 30-35% of market demand.
Typical user case (Q4 2025): A CMO in Europe (Switzerland) produced 15 different biologics (mAbs, fusion proteins, enzymes) for 12 clients, with batch sizes ranging from 500 to 50,000 units per product (2 mL vials, 5 mL vials, and pre-filled syringes). Using customized single-use filling assemblies (Sartorius Flexsafe custom manifold with 0.2 μm filter, 3-meter tubing, 4-port manifold, and sterile connectors), changeover time between products decreased from 36 hours (stainless steel, requiring CIP/SIP) to 4 hours (single-use assembly replacement). Validation time reduced from 8 weeks per product (CIP/SIP validation, cleaning agent residue testing) to 2 weeks per product (extractables/leachables, assembly integrity testing). CMO increased product throughput by 30% (from 10 to 13 products per year per filling line) without additional capital investment. Assembly cost per batch: US800(customized)vs.US800(customized)vs.US 200 per batch amortized cost for stainless steel (including CIP/SIP chemicals, utilities, labor, and validation). Despite 4x higher consumable cost, the CMO achieved 20% lower total cost per batch due to reduced downtime and validation burden. The CMO has transitioned 80% of its filling lines to single-use technology (up from 40% in 2022). Gross profit margin for the CMO: 35% for single-use-enabled lines vs. 28% for stainless steel lines.
Policy and regulatory update (2025-2026): The U.S. FDA published guidance (August 2025) “Single-Use Systems in Aseptic Filling: Quality Considerations,” requiring (1) extractables and leachables testing for all fluid-contact components (including tubing, connectors, filters, bags) per USP <665> and <1665>, (2) integrity testing of sterile assemblies (pressure decay or bubble-point test) post-gamma irradiation, (3) biocompatibility testing (ISO 10993) for materials contacting drug product. The European Medicines Agency (EMA) adopted “Guideline on Single-Use Systems in Biologics Manufacture” (November 2025), recommending risk-based validation approach (low-risk: standard assemblies for well-characterized molecules; high-risk: customized assemblies for novel biologics requiring full extractables profile). China’s NMPA updated “Guidelines for Single-Use Filling Assembly Registration” (February 2026), requiring (1) gamma irradiation validation (25-50 kGy, dose mapping studies), (2) bacterial challenge test (breach detection), and (3) 12-month stability study (sterility, integrity, functional performance). Domestic manufacturers (LePure Biotech, Cobetter Filtration) have obtained NMPA registration for 20+ assembly configurations, accelerating import substitution.
4. Competitive Landscape & Regional Market Share Dynamics
The Pharmaceutical Single-Use Filling Assemblies market is segmented as below:
Key players:
Sartorius (Germany – Flexsafe, Biostat assemblies), Thermo Fisher Scientific (US – SteriFill, Patheon single-use assemblies), Merck (Germany – Millipore custom assemblies, Mobius), Avantor (US – MasterFlex assemblies, filling components), Cytiva (US – ReadyToProcess assemblies), LePure Biotech (China – LePure single-use assemblies), Saint-Gobain (France – Tygon, PharmED tubing assemblies), Parker Hannifin (US – single-use connectors, manifolds), Entegris (US – Aseptic fill assemblies), Corning (US – cell culture and filling assemblies), Cobetter Filtration (China – Cobetter single-use systems), ZACROS (Japan – Z-Pak assemblies), Repligen (US – XCell ATF, filling assemblies), AdvantaPure (US – custom assemblies), Colder Products Company (US – single-use connectors, assemblies)
Segment by Assembly Type:
- Universal (Standard) Assemblies – 35-40% of market share by volume, lower by value
- Customized Assemblies – 60-65% of market share by value, fastest-growing
Segment by End-User:
- Pharmaceutical Industry (large pharma, biotech) – 60-65% of demand
- CMO Company (contract manufacturing organizations) – 30-35% of demand, fastest-growing
- Others (research institutions, clinical trial supply) – 5-10% of demand
Regional market share estimates 2025 (value):
- North America: 40% (US 36%, Canada 4%) – Largest biologics and CMO presence
- Europe: 30% (Germany 9%, Switzerland 6%, UK 5%, France 4%, others 6%) – Strong single-use adoption, EU GMP leadership
- Asia-Pacific: 25% (China 12%, Japan 5%, South Korea 4%, Singapore 2%, India 2%) – Fastest-growing, domestic suppliers gaining share
- Rest of World: 5% (Latin America, Middle East)
Exclusive insight (原创观察): A critical and underreported dynamic is the divergence in single-use filling assembly adoption between large pharmaceutical companies (fully integrated, validation-intensive, high cost tolerance) and small biotech/CDMOs (cost-sensitive, flexible, rapid scale-up). Large pharma (Roche, J&J, Merck) have transitioned 70-80% of their filling lines to single-use for biologics and vaccines, driven by multi-product facilities (20-50 products per site) and regulatory benefits (reduced cleaning validation). Small biotechs and specialized CDMOs use single-use assemblies for all products (90-100% adoption) due to lack of stainless steel CIP/SIP infrastructure and need for rapid (3-6 month) facility deployment. By 2028, we project single-use adoption will reach 85-95% for biologics (up from 60-70% in 2025) and 50-60% for small molecule sterile injectables (up from 30-40%). The remaining stainless steel filling lines will be dedicated to high-volume, single-product facilities (e.g., insulin, heparin, generic injectables), where product changeover is infrequent. This bifurcation means single-use filling assembly market share of the total fill-finish equipment market will increase from 30-35% to 50-55% by 2030.
5. Technical Hurdles and Future Research Directions
Despite rapid adoption, significant technical and operational challenges remain:
- High upfront cost and cost-effectiveness concerns: Single-use assemblies (US200−1,500each)havehigherper−batchconsumablecostthanstainlesssteel(US200−1,500each)havehigherper−batchconsumablecostthanstainlesssteel(US 50-200 amortized cost). For high-volume products (>1 million units annually, >20 batches per year), stainless steel may be more cost-effective (breakeven point: 15-30 batches per year). Some pharmaceutical companies hesitate to fully transition due to concerns about waste generation, environmental sustainability (plastic incineration), and long-term cost-effectiveness. CMOs face acute pressure: clients demand low per-unit cost, while single-use assembly cost can be 3-5% of COGS for high-volume products.
- Extractables and leachables (E&L) testing burden: For customized assemblies (different tubing, connectors, filters, bag films), full E&L testing (per USP <665>, <1665>, BPOG guidelines) costs US 50,000-200,000 per assembly configuration and requires 3-6 months. For biotech companies with 5-10 products in development (each requiring 3-5 assembly configurations), E&L testing can cost US 1-5 million and delay regulatory submissions by 6-12 months. Standardization of component materials (e.g., platinum-cured silicone tubing, polycarbonate connectors, PVDF filters) across suppliers could reduce E&L burden (shared extractables database), but competition limits cooperation.
- Material compatibility for sensitive biologics: Certain biologics (mAbs, fusion proteins, enzymes) adsorb to or interact with single-use materials (silicone tubing, polycarbonate connectors, polysulfone filter housings), causing product loss (10-30% yield reduction) or aggregation (impurity formation). Low-protein-binding materials (PVDF, PTFE, polypropylene, glass-coated stainless steel) reduce adsorption but increase assembly cost (50-100% premium). Validating material compatibility for each new biologic (2-6 months, US$ 100,000-500,000) is a significant burden for small biotechs.
Future Market Research priorities should address:
- Standardized extractables/leachables databases – Industry-wide collaboration (BPOG, BPSA, PDA) to create shared E&L databases for commonly used single-use materials (platinum-cured silicone, C-Flex, AdvantaFlex, polycarbonate, polysulfone). Reducing per-assembly E&L testing from US50,000−200,000toUS50,000−200,000toUS 10,000-20,000 (80% reduction). Early progress: BPOG published “Standardized Extractables Protocol for Single-Use Systems” (2024), but adoption is voluntary.
- Biodegradable and recyclable single-use materials – Developing polyolefin-based (polyethylene, polypropylene) films and tubing compatible with pharmaceutical manufacturing (low extractables, gamma stable) that can be recycled (not incinerated). ZACROS (Japan) launched polyethylene-based single-use assemblies (2025) for Japanese market; US and EU adoption pending.
- Integrated sensors and in-line quality monitoring – Single-use assemblies with embedded sensors (pressure, temperature, pH, conductivity, turbidity, and particle counting) for real-time quality monitoring during filling. Reduces need for end-of-line QC testing (accelerating release). Sartorius and Thermo Fisher launched sensor-integrated assemblies (2025) for high-risk biologics; 30-50% price premium.
- Standardized connector interfaces – ASME BPE standard for single-use connectors (2025 revision) and ASTM E3210 (sterile connectors) improving interoperability between suppliers. Reduced risk of cross-threading, leakage, and assembly errors (currently 1-3% of assemblies require rework or cause line stoppages).
- Gamma irradiation validation and alternative sterilization – Electron beam (e-beam) and X-ray sterilization for single-use assemblies (lower impact on materials, faster cycle time, no cobalt-60 supply chain constraints). Sartorius and Merck received FDA approval for e-beam sterilized assemblies (2025) for select configurations; adoption expanding 2026-2028.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
